COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit. Multicentric non-inferiority randomised controlled trial

Conditions

Intensive Care, Ventilator-associated Pneumonia

Brief summary

vital status at day 28

Detailed description

vital status at day 28, number of mechanical ventilation-free-days from inclusion to day 28 or death., Clinical, biological and radiological cure evaluated 7 to 10 days after VAP diagnosis, defined as the combination of resolution of signs and symptoms present at enrolment, biological improvement, and improvement or lack of progression of radiological signs, as adjudicated by an independent committee (PROBE methodology), new episode of VAP with the same Enterobacteriaceae, ICU length of stay, hospital length of stay, number of antibiotic free-days from inclusion to day 28 or death., safety (rate of allergy due to antimicrobial drug), ecological impact: o evolution of rate of MDR bacterial colonization on systematic screening at enrolment until ICU discharge, diagnostic of Clostridioides difficile infection between inclusion and day 28, Vital Status at day 90

Related papers

No related papers found yet.

Interventions

DRUGIMIPENEM MONOHYDRATE

DRUGMEROPENEM

DRUGOFLOXACIN

DRUGCEFEPIME

DRUGTEMOCILLIN

DRUGLEVOFLOXACIN

DRUGCIPROFLOXACIN

DRUGAMOXICILLIN

DRUGAZTREONAM

DRUGCO-TRIMOXAZOLE

DRUGERTAPENEM

DRUGAMOXICILLIN SODIUM

DRUGCEFTRIAXONE

DRUGPIPERACILLIN SODIUM

DRUGPIPERACILLIN

DRUGCEFOTAXIME

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
vital status at day 28	—

Secondary

Measure	Time frame
vital status at day 28, number of mechanical ventilation-free-days from inclusion to day 28 or death., Clinical, biological and radiological cure evaluated 7 to 10 days after VAP diagnosis, defined as the combination of resolution of signs and symptoms present at enrolment, biological improvement, and improvement or lack of progression of radiological signs, as adjudicated by an independent committee (PROBE methodology), new episode of VAP with the same Enterobacteriaceae, ICU length of stay, hospital length of stay, number of antibiotic free-days from inclusion to day 28 or death., safety (rate of allergy due to antimicrobial drug), ecological impact: o evolution of rate of MDR bacterial colonization on systematic screening at enrolment until ICU discharge, diagnostic of Clostridioides difficile infection between inclusion and day 28, Vital Status at day 90	—

Measure

Time frame

vital status at day 28, number of mechanical ventilation-free-days from inclusion to day 28 or death., Clinical, biological and radiological cure evaluated 7 to 10 days after VAP diagnosis, defined as the combination of resolution of signs and symptoms present at enrolment, biological improvement, and improvement or lack of progression of radiological signs, as adjudicated by an independent committee (PROBE methodology), new episode of VAP with the same Enterobacteriaceae, ICU length of stay, hospital length of stay, number of antibiotic free-days from inclusion to day 28 or death., safety (rate of allergy due to antimicrobial drug), ecological impact: o evolution of rate of MDR bacterial colonization on systematic screening at enrolment until ICU discharge, diagnostic of Clostridioides difficile infection between inclusion and day 28, Vital Status at day 90

—

Countries

France

Outcome results

None listed